Stockreport

Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington's Disease [Yahoo! Finance]

Sage Therapeutics, Inc.  (SAGE) 
Last sage therapeutics, inc. earnings: 2/27 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.sagerx.com/investor-relations
PDF HD-CAB) composite score at baseline between healthy participants and participants with Huntington's Disease (HD) prior to any treatment with dalzanemdor (SAGE-718) or pl [Read more]